Cat. No.: HY-B0307

Idoxuridine

(Synonyms: 5-Iodo-2′-deoxyuridine; 5-IUdR; IdUrd)

12 Cited Publications

Avis client

Based on 12 publication(s) in Google Scholar

Idoxuridine (5-Iodo-2′-deoxyuridine, 5-IUdR, IdUrd) is an iodinated thymidine analogue that competitively inhibits phosphorylases. Idoxuridine can inhibit viral activity, particularly viral eye infections, including herpes simplex keratitis, by inhibiting DNA polymerase and affecting viral replication. Idoxuridine against feline herpesvirus has the IC₅₀ value of 4.3 μM. Idoxuridine shows anti-orthopoxvirus activity.

Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.

Pureté: 99.81%
CAS No.: 54-42-2
Formule: C₉H₁₁IN₂O₅
Masse moléculaire:354.10

Stockage:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month

Idoxuridine Chemical Structure

CAS No.: 54-42-2

Size

Prix

Stock

Quantité

Amount: USD 0.00

* Veuillez sélectionner la quantité avant d'ajouter des articles.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Activité biologique
- Description
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (12)
Solvant et solubilité
- In Vitro
- In Vivo
Pureté et documentation
Références
Help & FAQs
Classifications
Bioz

Activité biologique

Description

IC₅₀ & Target^[4]

HSV-1

DNA Polymerase

Voir tous les produits spécifiques à Isoform DNA/RNA Synthesis :

Cellular Effect

Cell Line	Type	Value	Description	References
143B	CC₅₀	0.007 M Compound: IUDR	In vitro cell cytotoxicity against 143-B cell lines (Human osteosarcoma cell line) In vitro cell cytotoxicity against 143-B cell lines (Human osteosarcoma cell line)	[PMID: 12620076]
143B	CC₅₀	0.0074 M Compound: IUDR	In vitro cell cytotoxicity against 143B-LTK cell lines expressed in HSV-1 TK In vitro cell cytotoxicity against 143B-LTK cell lines expressed in HSV-1 TK	[PMID: 12620076]
143B	CC₅₀	7.0 x 10^-3 M Compound: IUDR	In vitro cell cytotoxicity was determined against 143B cell line In vitro cell cytotoxicity was determined against 143B cell line	[PMID: 15027876]
143B	CC₅₀	0.0001 M Compound: IUDR	In vitro cell cytotoxicity was determined against 143B-LTK cell line In vitro cell cytotoxicity was determined against 143B-LTK cell line	[PMID: 15027876]
143B	CC₅₀	0.1 mM Compound: IUDR	In vitro cell cytotoxicity was determined against 143B-LTK cell line In vitro cell cytotoxicity was determined against 143B-LTK cell line	[PMID: 15027876]
A549	EC₅₀	>100 μM Compound: 4; IDU	Cytotoxicity against human A549 cells assessed as reduction in cell viability after 72 hrs by MTS assay Cytotoxicity against human A549 cells assessed as reduction in cell viability after 72 hrs by MTS assay	[PMID: 27032331]
EMT6	CC₅₀	3.8 x 10^-4 M Compound: IUDR	In vitro cell cytotoxicity was determined against EMT-6 cell line In vitro cell cytotoxicity was determined against EMT-6 cell line	[PMID: 15027876]
HEL	CC₅₀	>50 μg/mL Compound: IDU	Tested for the cytotoxic concentration, required to reduce cell growth by 50% in human embryonic lung (HEL) cells. Tested for the cytotoxic concentration, required to reduce cell growth by 50% in human embryonic lung (HEL) cells.	[PMID: 7877148]
HEL	IC₅₀	>50 μg/mL Compound: IDU	Tested for the inhibitory concentration required to reduce cytomegalovirus (CMV) strain Davis plaque formation by 50%. Tested for the inhibitory concentration required to reduce cytomegalovirus (CMV) strain Davis plaque formation by 50%.	[PMID: 7877148]
HEL	IC₅₀	0.17 μg/mL Compound: IDU	Tested for the inhibitory concentration required to reduce TK+ Varicella-Zoster virus (TK+ VZV) strain OKA plaque formation by 50%. Tested for the inhibitory concentration required to reduce TK+ Varicella-Zoster virus (TK+ VZV) strain OKA plaque formation by 50%.	[PMID: 7877148]
HEL	IC₅₀	0.4 μg/mL Compound: IDU	Tested for the 50% inhibitory concentration required to reduce TK+ Varicella-Zoster virus (TK+ VZV) strain YS plaque formation by 50% Tested for the 50% inhibitory concentration required to reduce TK+ Varicella-Zoster virus (TK+ VZV) strain YS plaque formation by 50%	[PMID: 7877148]
HEL	IC₅₀	20 μg/mL Compound: IDU	Tested for the inhibitory concentration required to reduce cytomegalovirus (CMV) strain AD-169 plaque formation by 50%. Tested for the inhibitory concentration required to reduce cytomegalovirus (CMV) strain AD-169 plaque formation by 50%.	[PMID: 7877148]
HEL	IC₅₀	4 μg/mL Compound: IDU	Tested for the inhibitory concentration required to reduce thymidine kinase deficient Varicella-Zoster virus (TK- VZV) strain 07/1 plaque formation by 50%. Tested for the inhibitory concentration required to reduce thymidine kinase deficient Varicella-Zoster virus (TK- VZV) strain 07/1 plaque formation by 50%.	[PMID: 7877148]
HEL	IC₅₀	4 μg/mL Compound: IDU	Tested for the inhibitory concentration required to reduce thymidine kinase deficient Varicella-Zoster virus (TK- VZV) strain YS/R plaque formation by 50%. Tested for the inhibitory concentration required to reduce thymidine kinase deficient Varicella-Zoster virus (TK- VZV) strain YS/R plaque formation by 50%.	[PMID: 7877148]
HFF	CC₅₀	>260 μM Compound: 5-iodo-2'-deoxyuridine	Cytotoxicity against HFF cells by neutral red uptake assay Cytotoxicity against HFF cells by neutral red uptake assay	[PMID: 16821766]
HFF	EC₅₀	0.4 μM Compound: 5-iodo-2'-deoxyuridine	Antiviral activity against TK+ cowpox virus delta crmA in HFF cells Antiviral activity against TK+ cowpox virus delta crmA in HFF cells	[PMID: 16821766]
HFF	EC₅₀	2 μM Compound: 5-iodo-2'-deoxyuridine	Antiviral activity against cowpox virus in HFF cells by plaque reduction assay Antiviral activity against cowpox virus in HFF cells by plaque reduction assay	[PMID: 16821766]
HFF	EC₅₀	27 μM Compound: 5-iodo-2'-deoxyuridine	Antiviral activity against TK- cowpox virus TK:GFP lacZ in HFF cells Antiviral activity against TK- cowpox virus TK:GFP lacZ in HFF cells	[PMID: 16821766]
HFF	EC₅₀	6 μM Compound: 5-iodo-2'-deoxyuridine	Antiviral activity against vaccinia virus in HFF cells by plaque reduction assay Antiviral activity against vaccinia virus in HFF cells by plaque reduction assay	[PMID: 16821766]
HFF	EC₅₀	1.1 μM Compound: IDU, idoxuridine	Antiviral activity against TK+ Cowpox virus Delta crmA in HFF cells after 48 hrs by beta-galactosidase assay Antiviral activity against TK+ Cowpox virus Delta crmA in HFF cells after 48 hrs by beta-galactosidase assay	[PMID: 17325220]
HFF	EC₅₀	1.8 μM Compound: IDU, idoxuridine	Antiviral activity against Cowpox virus Brighton in HFF cells after 1 hr by plaque reduction assay Antiviral activity against Cowpox virus Brighton in HFF cells after 1 hr by plaque reduction assay	[PMID: 17325220]
HFF	EC₅₀	5.6 μM Compound: IDU, idoxuridine	Antiviral activity against Vaccinia virus in HFF cells after 1 hr by plaque reduction assay Antiviral activity against Vaccinia virus in HFF cells after 1 hr by plaque reduction assay	[PMID: 17325220]
HFF	EC₅₀	76 μM Compound: IDU, idoxuridine	Antiviral activity against TK- Cowpox virus TK:GFP lacZ in HFF cells after 48 hrs by beta-galactosidase assay Antiviral activity against TK- Cowpox virus TK:GFP lacZ in HFF cells after 48 hrs by beta-galactosidase assay	[PMID: 17325220]
Huh-7	CC₅₀	>282 μM Compound: 28	Cytotoxicity against HuH7 cells Cytotoxicity against HuH7 cells	[PMID: 20857959]
Jurkat	EC₅₀	79.7 μM Compound: 4; IDU	Cytotoxicity against human Jurkat cells assessed as reduction in cell viability after 72 hrs by MTS assay Cytotoxicity against human Jurkat cells assessed as reduction in cell viability after 72 hrs by MTS assay	[PMID: 27032331]
KBALB-STK	CC₅₀	1.0 x 10^-5 M Compound: IUDR	In vitro cell cytotoxicity against KBALB-STK cell lines expressed in HSV-1 TK In vitro cell cytotoxicity against KBALB-STK cell lines expressed in HSV-1 TK	[PMID: 12620076]
KBALB-STK	CC₅₀	1.0 x 10^-5 M Compound: IUDR	In vitro cell cytotoxicity was determined against KBALB-STK cell line In vitro cell cytotoxicity was determined against KBALB-STK cell line	[PMID: 15027876]
L5178Y	IC₅₀	2.4 μM Compound: IdUrd	In vitro growth inhibition of FdUrd resistant L5178Y-Resistant murine leukemia cells In vitro growth inhibition of FdUrd resistant L5178Y-Resistant murine leukemia cells	[PMID: 11101356]
L5178Y	IC₅₀	3.8 μM Compound: IdUrd	In vitro growth inhibition of L5178Y-Parental murine leukemia cells In vitro growth inhibition of L5178Y-Parental murine leukemia cells	[PMID: 11101356]
L5178Y	IC₅₀	4.6 μM Compound: IdUrd	In vitro growth inhibition of L5178Y-Parental murine leukemia cells by incorporation of [14C]Leu. In vitro growth inhibition of L5178Y-Parental murine leukemia cells by incorporation of [14C]Leu.	[PMID: 11101356]
L5178Y	IC₅₀	5.4 μM Compound: IdUrd	In vitro growth inhibition of L5178Y-Parental murine leukemia cells by incorporation of [14C]-Thd. In vitro growth inhibition of L5178Y-Parental murine leukemia cells by incorporation of [14C]-Thd.	[PMID: 11101356]
NC-37	CC₅₀	80 μg/mL Compound: IDU	Cytotoxic concentration required to inhibit NC-37 cells by 50% Cytotoxic concentration required to inhibit NC-37 cells by 50%	10.1016/S0960-894X(01)80146-3
NC-37	EC₅₀	>80 μg/mL Compound: IDU	Concentration required to reduce HSV-1 (KOS strain) induced cytopathogenicity in NC-37 cells Concentration required to reduce HSV-1 (KOS strain) induced cytopathogenicity in NC-37 cells	10.1016/S0960-894X(01)80146-3
PC-3	EC₅₀	>100 μM Compound: 4; IDU	Cytotoxicity against human PC3 cells assessed as reduction in cell viability after 72 hrs by MTS assay Cytotoxicity against human PC3 cells assessed as reduction in cell viability after 72 hrs by MTS assay	[PMID: 27032331]
PRK	IC₅₀	0.1 μg/mL Compound: 5-I-2'-d Urd	Concentration required to reduce HSV-1 induced cytopathogenicity by 50% in primary rabbit kidney (PRK) cells Concentration required to reduce HSV-1 induced cytopathogenicity by 50% in primary rabbit kidney (PRK) cells	[PMID: 6267280]
PRK	IC₅₀	0.2 μg/mL Compound: 5-I-2'-d Urd	Concentration required to reduce HSV-2 induced cytopathogenicity by 50% in primary rabbit kidney (PRK) cells; 0.2-0.4 Concentration required to reduce HSV-2 induced cytopathogenicity by 50% in primary rabbit kidney (PRK) cells; 0.2-0.4	[PMID: 6267280]
PRK	IC₅₀	0.3 μg/mL Compound: 5-I-2'-d Urd	Concentration required to inhibit incorporation of [1,'2'-3H]dUrd into DNA of primary rabbit kidney (PRK) cells by 50% Concentration required to inhibit incorporation of [1,'2'-3H]dUrd into DNA of primary rabbit kidney (PRK) cells by 50%	[PMID: 6267280]
PRK	IC₅₀	0.4 μg/mL Compound: 5-I-2'-d Urd	Compound was evaluated for antiviral activity in rabbit kidney cells infected with vaccinia virus Compound was evaluated for antiviral activity in rabbit kidney cells infected with vaccinia virus	[PMID: 6267280]
PRK	IC₅₀	1 μg/mL Compound: 5-I-2'-d Urd	Concentration required to inhibit incorporation of [Me-3H]-dThd into DNA of primary rabbit kidney (PRK) cells by 50% Concentration required to inhibit incorporation of [Me-3H]-dThd into DNA of primary rabbit kidney (PRK) cells by 50%	[PMID: 6267280]
PRK	IC₅₀	200 μg/mL Compound: 5-I-2'-d Urd	Concentration required to reduce TK-HSV-1 (B2006) induced cytopathogenicity by 50% in primary rabbit kidney (PRK) cells Concentration required to reduce TK-HSV-1 (B2006) induced cytopathogenicity by 50% in primary rabbit kidney (PRK) cells	[PMID: 6267280]
Ramos	EC₅₀	47.9 μM Compound: 4; IDU	Cytotoxicity against human Ramos cells assessed as reduction in cell viability after 72 hrs by MTS assay Cytotoxicity against human Ramos cells assessed as reduction in cell viability after 72 hrs by MTS assay	[PMID: 27032331]
U-87MG ATCC	EC₅₀	>100 μM Compound: 4; IDU	Cytotoxicity against human U87 cells assessed as reduction in cell viability after 72 hrs by MTS assay Cytotoxicity against human U87 cells assessed as reduction in cell viability after 72 hrs by MTS assay	[PMID: 27032331]
Vero	CC₅₀	6.8 μM Compound: IUdR	Cytotoxicity against african green monkey Vero cells after 2 days Cytotoxicity against african green monkey Vero cells after 2 days	[PMID: 17438061]
Vero	EC₅₀	11.2 μM Compound: IUdR	Antiviral activity against Herpes B virus 24105 infected in african green monkey Vero cells assessed as plaque reduction after 36 to 48 hrs Antiviral activity against Herpes B virus 24105 infected in african green monkey Vero cells assessed as plaque reduction after 36 to 48 hrs	[PMID: 17438061]
Vero	EC₅₀	2.8 μM Compound: IUdR	Antiviral activity against Herpes simplex virus 1 F infected in african green monkey Vero cells assessed as plaque reduction after 36 to 48 hrs Antiviral activity against Herpes simplex virus 1 F infected in african green monkey Vero cells assessed as plaque reduction after 36 to 48 hrs	[PMID: 17438061]
Vero	EC₅₀	8.5 μM Compound: IUdR	Antiviral activity against Herpes B virus 32425 infected in african green monkey Vero cells assessed as plaque reduction after 36 to 48 hrs Antiviral activity against Herpes B virus 32425 infected in african green monkey Vero cells assessed as plaque reduction after 36 to 48 hrs	[PMID: 17438061]
Vero	ED₅₀	1.2 μM Compound: IDU	In vitro antiviral activity by means of plaque-inhibition assay with monolayers of Vero cells infected with the MP strain of herpes simplex virus-1 (HSV-1) In vitro antiviral activity by means of plaque-inhibition assay with monolayers of Vero cells infected with the MP strain of herpes simplex virus-1 (HSV-1)	[PMID: 6086926]

In Vitro

Idoxuridine (2-10 μM, 72 hours) has the IC₅₀ value of 4.3 μM of antiviral^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Proliferation Assay^[1]

Cell Line:

Crandell-Reese feline kidney (CRFK) cells
Concentration:

2-10 μM
Incubation Time:

72 hours
Result:

Showed the IC₅₀ value of 4.3 μM.

Cell Cytotoxicity Assay^[1]

Cell Line:

Crandell-Reese feline kidney (CRFK) cells
Concentration:

5-50 μM
Incubation Time:

72 hours
Result:

Reduced by 10.8% relatively in CRFK cells.

In Vivo

Idoxuridine (intraperitoneal injection, 50-200 mg/kg, 3 times, 3 hours interval) can stimulate the production of hemolysin plaque-forming cells (HPFC) to sheep red blood cells (SRBC) in C3HeB/FeJ female and male mice and A/J male mice^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

C3HeB/FeJ female and male mice and A/J male mice, aged 2 to 4 months^[2]
Dosage:

50-200 mg/kg
Administration:

Intraperitoneal injection, 3 times, 3 hours interval
Result:

Stimulated the production of hemolysin plaque-forming cells (HPFC) to sheep red blood cells (SRBC) in the dose range of 50-200 mg/kg.

Chemical Information

CAS No. 54-42-2
Appearance Solid
Masse moléculaire 354.10
Formule C₉H₁₁IN₂O₅
Color White to off-white
SMILES

O=C(N1)N([C@H]2C[C@H](O)[C@@H](CO)O2)C=C(I)C1=O
Synonyms

5-Iodo-2′-deoxyuridine; 5-IUdR; IdUrd
Livraison

Room temperature in continental US; may vary elsewhere.

Stockage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Publications (12)

All Cell Imaging/StainingCell Proliferation/Viability AssayBio/Physico-chemical Assay

Sort by:

Journal Impact Factor

Genes Dis

2025 Oct 21.
Adv Sci (Weinh)

DMAP1 Deficiency Suppresses Lung Cancer Progression by Destabilizing Replication Fork and Activating IFN Signaling-Mediated Anti-tumor Immunity. [Abstract]

2026 Jun;13(33):e17634. PMID: 41904944
Cell Death Differ

NKAP acts with HDAC3 to prevent R-loop associated genome instability. [Abstract]

2023 Jul;30(7):1811-1828. PMID: 37322264
Cell Death Dis

PHF20 stabilizes the GAS7-F-actin axis to drive DNA damage repair and chemoresistance in cutaneous squamous cell carcinoma. [Abstract]

2026 May 29. PMID: 42215448
Sci China Life Sci

SETD3-mediated histidine methylation of MCM7 regulates DNA replication by facilitating chromatin loading of MCM. [Abstract]

2025 Mar;68(3):793-808. PMID: 39455502
Oncogene

Synergistic lethality between PARP-trapping and alantolactone-induced oxidative DNA damage in homologous recombination-proficient cancer cells. [Abstract]

2020 Apr;39(14):2905-2920. PMID: 32029902

Idoxuridine purchased from MedChemExpress. Usage Cited in: Oncogene. 2020 Apr;39(14):2905-2920. [Abstract]

Representative images of CIdU and Idoxuridine (IdU, 25 μM, 30 μM) positive PC-3 cells (scale bar: 25 μm).

Idoxuridine purchased from MedChemExpress. Usage Cited in: Oncogene. 2020 Apr;39(14):2905-2920. [Abstract]

The percentage of CIdU and Idoxuridine (IdU, 25 μM, 30 μM) positive cells in three wells.
Emerg Microbes Infect

The assessment on cross immunity with smallpox virus and antiviral drug sensitivity of the isolated mpox virus strain WIBP-MPXV-001 in China. [Abstract]

2023 Dec;12(1):2208682. PMID: 37128898

Idoxuridine purchased from MedChemExpress. Usage Cited in: Emerg Microbes Infect. 2023 Dec;12(1):2208682. [Abstract]

The cytotoxicity test results of the drug showed that the CC₅₀ of Tecovinimat was 21.95 μM, the CC₅₀ of Idoxuridine was 18.33 μM, the CC₅₀ of Brincidofovir was 17.87 μM, and the CC₅₀ of Cidovir > 200 μM.
Virology

5-Bromo-2'-deoxyuridine inhibits African swine fever virus (ASFV) replication via interfering viral DNA replication and suppressing the formation of viral factories. [Abstract]

2024 Sep 12:600:110237. PMID: 39288610
University of North Carolina at Chapel Hill

2025.
bioRxiv

AURKA inhibition amplifies DNA replication stress to foster WEE1 kinase dependency and synergistic antitumor effects with WEE1 inhibition in cancers. [Abstract]

2025 May 29:2025.05.28.656693. PMID: 40501675
bioRxiv

The RING Finger E3 Ligase RNF25 Protects DNA Replication Forks Independently of its Canonical Roles in Ubiquitin Signaling. [Abstract]

2025 Jan 9:2025.01.09.632184. PMID: 39829812

Idoxuridine purchased from MedChemExpress. Usage Cited in: bioRxiv. 2025 Jan 9:2025.01.09.632184. [Abstract]

Bottom: RNF25^+/+ and RNF25^−/− Pa02C and Pa03C cells were labeled with CldU and Idoxuridine (IdU) (250 μM) and fork speed was calculated by dividing tract lengths by total pulse time.

Idoxuridine purchased from MedChemExpress. Usage Cited in: bioRxiv. 2025 Jan 9:2025.01.09.632184. [Abstract]

Top: Schematic of fork degradation assays. Bottom: RNF25^+/+ and RNF25^−/− Pa02C and Pa03C cells were labeled with CldU and Idoxuridine (IdU) (250 μM), then treated with HU to induce fork stalling. The ratio of IdU to CldU tracts was used as a readout of fork degradation.
SSRN

2023 Mar 20.

Solvant et solubilité

In Vitro:

DMSO : 100 mg/mL (282.41 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

H₂O : 2.5 mg/mL (7.06 mM; ultrasonic and warming and heat to 60°C)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.8241 mL

14.1203 mL

28.2406 mL

5 mM

0.5648 mL

2.8241 mL

5.6481 mL

10 mM

0.2824 mL

1.4120 mL

2.8241 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Calculateur de molarité

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Calculateur de dilution

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.08 mg/mL (5.87 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.08 mg/mL (5.87 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.08 mg/mL (5.87 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Pureté et documentation

Select Batch:

Pureté: 99.98%

Assay: 99.98%

ee.: 99.98%

Fiche technique (281 KB)
SDS (557 KB)
- English - EN (557 KB)
- Français - FR (557 KB)
- Deutsch - DE (557 KB)
- Norwegian - NO (557 KB)
- Español - ES (557 KB)
- Swedish - SV (557 KB)
- Italian - IT (557 KB)
- Korean - KR (557 KB)
- Portuguese - PT (557 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Instruction de manipulation (2659 KB)

Références

[1]. David J Maggs, et al. In vitro efficacy of ganciclovir, cidofovir, penciclovir, foscarnet, idoxuridine, and acyclovir against feline herpesvirus type-1. Am J Vet Res. 2004 Apr;65(4):399-403. [Content Brief]

[2]. D E Griswold, et al. Stimulation of hemolysin plaque-forming cells by idoxuridine. Cancer Res. 1975 Jan;35(1):88-92. [Content Brief]

[3]. Mark N Prichard, et al. Orthopoxvirus targets for the development of antiviral therapies. Curr Drug Targets Infect Disord [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
H₂O / DMSO	1 mM	2.8241 mL	14.1203 mL	28.2406 mL	70.6015 mL
H₂O / DMSO	5 mM	0.5648 mL	2.8241 mL	5.6481 mL	14.1203 mL
DMSO	10 mM	0.2824 mL	1.4120 mL	2.8241 mL	7.0602 mL
	15 mM	0.1883 mL	0.9414 mL	1.8827 mL	4.7068 mL
	20 mM	0.1412 mL	0.7060 mL	1.4120 mL	3.5301 mL
	25 mM	0.1130 mL	0.5648 mL	1.1296 mL	2.8241 mL
	30 mM	0.0941 mL	0.4707 mL	0.9414 mL	2.3534 mL
	40 mM	0.0706 mL	0.3530 mL	0.7060 mL	1.7650 mL
	50 mM	0.0565 mL	0.2824 mL	0.5648 mL	1.4120 mL
	60 mM	0.0471 mL	0.2353 mL	0.4707 mL	1.1767 mL
	80 mM	0.0353 mL	0.1765 mL	0.3530 mL	0.8825 mL
	100 mM	0.0282 mL	0.1412 mL	0.2824 mL	0.7060 mL

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Keywords

Idoxuridine

12 Cited Publications

100 mg Obtenir un devis

Subscribe to the

MedChemExpress

Newsletter

Nom du produit:
Cat. No.:
Quantité:
MCE Japan Authorized Agent:

Nom du produit:
CAS No.:
Species:
Pureté:
Quantité:

Idoxuridine

Anti-Infection Compound Library

Cell Cycle/DNA Damage Compound Library

Metabolism/Protease Compound Library

FDA-Approved Drug Library

Anti-Cancer Compound Library

Antiviral Compound Library

Anti-Aging Compound Library

Drug Repurposing Compound Library

Nucleotide Compound Library

Anti-COVID-19 Compound Library

NMPA-Approved Drug Library

FDA Approved & Pharmacopeial Drug Library

Phosphatase Inhibitor Library

Rare Diseases Drug Library

FDA-Approved Anticancer Drug Library

Human Metabolite Library

Anti-Orthopoxvirus Compound Library

Off-patent Drug Library

Metabolic Enzyme Compound Library

Highly Selective Inhibitors Library

Multi-Target Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Mass Spectrometry Human Metabolite Library

Publications Citing Use of MedChemExpress (MCE) Idoxuridine

Voir tous les produits spécifiques à Isoform DNA/RNA Synthesis

Activité biologique

Chemical Information

Publications (12)

Solvant et solubilité

Pureté et documentation

Références

Help & FAQs

Complete Stock Solution Preparation Table

Idoxuridine

Anti-Infection Compound Library

Cell Cycle/DNA Damage Compound Library

Metabolism/Protease Compound Library

FDA-Approved Drug Library

Anti-Cancer Compound Library

Antiviral Compound Library

Anti-Aging Compound Library

Drug Repurposing Compound Library

Nucleotide Compound Library

Anti-COVID-19 Compound Library

NMPA-Approved Drug Library

FDA Approved & Pharmacopeial Drug Library

Phosphatase Inhibitor Library

Rare Diseases Drug Library

FDA-Approved Anticancer Drug Library

Human Metabolite Library

Anti-Orthopoxvirus Compound Library

Off-patent Drug Library

Metabolic Enzyme Compound Library

Highly Selective Inhibitors Library

Multi-Target Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Mass Spectrometry Human Metabolite Library

Publications Citing Use of MedChemExpress (MCE) Idoxuridine

Voir tous les produits spécifiques à Isoform DNA/RNA Synthesis

Activité biologique

Chemical Information

Publications (12)

Solvant et solubilité

Pureté et documentation

Références

Help & FAQs

Complete Stock Solution Preparation Table

Idoxuridine Related Classifications

HY-B0307 Related Classifications